MPOXED

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu

May 16, 2025

The continued lack of an effective antiviral treatment for mpox, especially the severe Clade 1a and 1b strains, highlights a critical unmet medical need in global public health. With case fatality rates as high as 3–4%—and children disproportionately affected—current responses rely solely on vaccines and supportive care. NanoViricides' Phase II trial of NV-387 in the Democratic Republic of Congo marks a significant step forward. If successful, NV-387 could become the first targeted oral antiviral for mpox, fulfilling a long-standing treatment gap and reinforcing global health security amid a persistent public health emergency.

Mpox activity escalates in Sierra Leone

May 15, 2025

The alarming rise of mpox cases in Sierra Leone—611 last week alone—demands urgent international attention. Representing over half of all cases in Africa, the outbreak’s rapid spread, particularly in Freetown and its surrounding districts, signals a critical risk of cross-border transmission. While testing coverage remains robust, weak contact tracing hampers containment. Africa CDC’s vaccination campaign has already reached over 30,000 people in two weeks, but with 6.4 million doses needed continent-wide, urgent global support is essential. Mpox remains a public health emergency, and sustained investment in vaccines, contact tracing, and community education will be key to halting its escalation.

Sierra Leone's mpox cases fuel African outbreak, health body says

May 8, 2025

Sierra Leone now accounts for over half of Africa’s confirmed mpox cases this week, with 384 new infections—marking a 63% surge and underscoring the country’s central role in driving the continent’s outbreak, according to the Africa CDC. Limited funding, insufficient contact tracing, and inadequate treatment capacity—only 60 beds for 800 active cases—are compounding the crisis. Although cases are declining in Uganda and Burundi and stabilizing in the DRC, Sierra Leone's escalation highlights the urgent need for strengthened surveillance and resources. With WHO maintaining mpox’s classification as a public health emergency, the international community must prioritize response funding.

Sierra Leone battles mpox surge

May 8, 2025

Mpox cases in Sierra Leone are surging dramatically, with the country now averaging 100 new infections daily and accounting for half of Africa’s confirmed cases last week. The outbreak, driven by clade 2b, predominantly affects males aged 30 to 35 and includes a significant number of patients with HIV. While nearly 24,000 people—mainly health workers—have been vaccinated, limited isolation beds and low contact-tracing capacity hinder containment. Despite this, Africa CDC reports promising progress in other high-burden countries like Uganda, Burundi, and the DRC. Continued vigilance, funding, and expanded vaccination remain vital to halt the virus’s spread across the region.

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines

May 6, 2025

Bavarian Nordic has secured a $143.6 million expansion of its contract with the U.S. government to supply freeze-dried JYNNEOS® smallpox/mpox vaccines, following FDA approval of the formulation in March 2025. The Biomedical Advanced Research and Development Authority (BARDA) exercised options to convert existing vaccine stock and support long-term shelf life, with deliveries expected in 2026. The freeze-dried version offers logistical advantages for national stockpiles. Since 2003, Bavarian Nordic has partnered with the U.S. on vaccine preparedness, and this latest investment underscores continued federal commitment to bolstering biosecurity and ensuring future mpox and smallpox response capacity.

Gavi delivers largest shipment yet to DRC in support of international mpox response

May 1, 2025

This week, the Democratic Republic of the Congo will receive 200,000 new mpox vaccine doses from Gavi, the Vaccine Alliance, bolstering the country’s response to one of the world’s most severe mpox outbreaks. With over 20,000 cases and 49 deaths reported by mid-April 2025, DRC has now received more than 950,000 doses in total. The new shipment will target high-risk regions, especially areas affected by mass displacement. This delivery, part of Gavi’s broader emergency response effort alongside WHO, Africa CDC, and UNICEF, underscores the critical importance of international solidarity in combatting Clade Ib mpox and preserving global public health.

United States (U.S.) Government Commits nearly $1 Million to Strengthen Mpox Response in Tanzania

April 29, 2025

The U.S. Centers for Disease Control and Prevention (CDC) has committed nearly $1 million to help Tanzania combat the spread of mpox. The funding will enhance infection surveillance, prevention, and control across both mainland Tanzania and Zanzibar. Resources will support health facilities, emergency operations centers, and public awareness campaigns, as well as bolster laboratory capacity and border screening. This collaboration reflects the U.S. government’s strategic investment in global health security, reinforcing Tanzania’s response capacity and safeguarding communities. Such partnerships are critical not only for local disease containment but also for preventing wider international transmission of emerging infectious threats like mpox.

Stockpiling for mpox emergencies

April 28, 2025

Recent mpox outbreaks have underscored the need for a sustainable global response. Gavi, the Vaccine Alliance, currently supports vaccine deployment in African countries and is planning to establish an emergency mpox vaccine stockpile. This initiative would ensure rapid response to future outbreaks and incentivize manufacturers to maintain production despite unpredictable demand. However, the creation of the stockpile depends on Gavi’s success in raising $9 billion for its 2026–2030 strategic cycle. A stockpile would move global health efforts beyond the current reliance on emergency donations and fragmented supplies, ensuring equitable and timely access to vaccines during future public health emergencies.

Mobile teams step up efforts to stop mpox

April 27, 2025

In North Kivu, Democratic Republic of the Congo, mpox cases are surging amid mass displacement caused by armed conflict. Over 3,300 suspected cases have been recorded this year. In response, UNICEF and partners have deployed 12 mobile vaccination teams to hard-hit areas like Goma. At Kabingo Primary School, children exposed to a confirmed case are receiving the vaccine to curb the spread. Community engagement is central to the campaign’s success, with students and parents advocating for vaccination after firsthand experiences with the disease. The initiative is supported by Gavi, the Mastercard Foundation, the UK FCDO, and the European Union.

Africa CDC to Review Mpox Emergency Status Amid Mixed Infection Trends

April 25, 2025

Africa CDC's Emergency Consultative Group will meet on 17 May 2025 to decide whether mpox should remain a public health emergency of continental concern. The review comes amid mixed epidemiological trends—while infections are falling in some countries like Burundi and Rwanda, others such as Uganda and Nigeria are seeing surges. Central Africa remains the epicentre, complicated by conflict, a drop in testing, and the emergence of a new Clade 1A variant. Meanwhile, vaccine rollout is expanding. The decision will influence future strategy, funding, and partnerships, with the updated response plan aiming to reduce incidence by 50% by August 2025.

African countries see payoff from ramped-up mpox strategies

April 25, 2025

Mpox cases in Africa have declined over the past six weeks, driven by intensified public health efforts like expanded community health worker contact tracing, according to Africa CDC officials. While Burundi and the DRC are showing promising declines, 17 of 24 affected countries still report active transmission. Malawi has newly confirmed community transmission of clade 1b mpox. Vaccination campaigns are scaling up, and rapid diagnostic tests are under evaluation to improve early case detection. Despite positive trends, officials remain cautious, citing conflicts, low testing rates, and concurrent outbreaks like measles as ongoing challenges to fully containing the virus.

Mpox Found in North Carolina Sewage: What to Know

April 24, 2025

North Carolina health officials are urging vigilance after clade I mpox virus was detected in wastewater samples from Greenville, signaling possible undiagnosed or unreported infections. The findings, uncovered through the state’s wastewater monitoring network, mark the first environmental detection of this more virulent mpox strain in the state. Although no confirmed clade I cases have been reported in North Carolina to date, officials stress the importance of monitoring symptoms and considering vaccination among high-risk groups. This alert underscores wastewater surveillance as an essential tool for early detection and community-level awareness in preventing potential mpox transmission.

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

April 24, 2025

Tonix Pharmaceuticals has unveiled promising preclinical data for TNX-801, a novel single-dose live-virus mpox vaccine, at the 2025 World Vaccine Congress. TNX-801, based on synthesized horsepox, showed strong protection against both rabbitpox and clade IIa mpox in animals—including immunocompromised models—after just one dose. The vaccine prevented clinical disease and lesion formation, supporting its potential as a safe, effective alternative to multi-dose vaccines. With mpox outbreaks involving clade IIb and clade Ib declared international emergencies by the World Health Organization, TNX-801’s alignment with WHO’s preferred vaccine profile strengthens its promise in bolstering global preparedness and rapid response to future epidemics.

Sierra Leone health workers line up for mpox jab amid growing outbreak

April 23, 2025

Sierra Leone has launched its first mpox vaccination campaign, prioritizing frontline health workers, close contacts of infected individuals, and security personnel. The drive follows a surge in cases since January, with 477 infections and three deaths. The 61,300 doses—58,300 from Gavi and the rest from Ireland—are being administered in hotspots, including at Freetown’s 34 Military Hospital. With community transmission now widespread, health officials are coupling immunization with public awareness campaigns to break the chain of infection. The campaign, backed by Africa CDC, WHO, and UNICEF, marks a crucial step in strengthening Sierra Leone’s outbreak response and protecting its most vulnerable.

Mpox detected in NC wastewater, health officials issue alert

April 22, 2025

North Carolina health officials are urging vigilance following the detection of Clade I mpox virus in wastewater samples from Greenville—the first such detection in the state. While no confirmed cases have been reported, the North Carolina Department of Health and Human Services warns that this could signal undiagnosed infections. Wastewater surveillance is an early-warning tool, and Clade I is a more severe strain linked to outbreaks in Central and Eastern Africa. Although public risk remains low, providers are advised to monitor symptoms and assess travel history. Funding for wastewater monitoring remains uncertain, posing a challenge for ongoing viral detection efforts.

Squirrels, Not Monkeys, May Be the Animal Source of Mpox, Researchers Suggest

April 18, 2025

A groundbreaking study in Ivory Coast has linked a deadly mpox outbreak among sooty mangabey monkeys to the fire-footed rope squirrel, providing the strongest evidence yet of this species' role in viral spillover. Researchers from the Helmholtz Institute traced the transmission from a squirrel consumed by a mother monkey to her offspring and then throughout the troop. This is the first confirmed cross-species transmission of mpox from a squirrel to primates in a wild setting. While further research is needed to determine if the rope squirrel is a reservoir host, the findings mark a critical step in understanding zoonotic mpox emergence.

Hospital contacts patients and staff over mpox case

April 17, 2025

Addenbrooke’s Hospital in Cambridge is investigating possible mpox exposure after a confirmed patient visited its emergency department. The hospital has contacted 30 patients and 20 staff who may have been in close proximity to assess risk and determine whether vaccines or symptom monitoring are necessary. The patient is now isolating at home. Though mpox, formerly known as monkeypox, was recently downgraded from a high-consequence infectious disease classification, it remains a public health concern due to its potential for close-contact transmission. UK Health Security Agency has been informed, and authorities stress that the public’s risk remains low.

Africa CDC and WHO update mpox strategy as outbreaks persist

April 17, 2025

Africa CDC and WHO have jointly updated their Continental Mpox Response Plan to reflect the growing urgency of the outbreak. With more than one million vaccine doses delivered and 650,000 administered—90% in the DRC—the revised plan focuses on controlling the outbreak while transitioning toward long-term resilience. Diagnostic capacity in the DRC has improved with 23 operational labs, but escalating conflict and aid cuts are hampering response efforts. Local transmission has now been reported in 11 African countries. The updated plan emphasizes sustained vaccination, diagnostics, and integration of mpox into routine health services to safeguard future public health.

Mpox is on the rise in Berlin with gay men seen most at risk

April 17, 2025

A sharp rise in mpox cases in Berlin has prompted health officials and LGBTQ+ advocates to call for an urgent vaccination campaign targeting gay and bisexual men. Berlin reported 43 cases in the first three months of 2025—quadruple the number during the same period in previous years. Unlike recent European cases tied to travel, most of Berlin’s cases are locally acquired, highlighting vaccine coverage gaps. While the infections are from Clade II and not the deadlier Clade Ib variant, public health experts emphasize that uninsured and newly arrived individuals must be reached through community-led, stigma-free health outreach and access.

Mpox drug Tpoxx didn't speed lesion healing in clade 1 patients, trial shows

April 17, 2025

A landmark clinical trial in the Democratic Republic of the Congo found that tecovirimat (Tpoxx), widely distributed for mpox treatment, was ineffective in accelerating healing or reducing pain for patients infected with clade 1 mpox. Published in the New England Journal of Medicine, the PALM007 study revealed no statistically significant differences in recovery time or mortality between patients treated with Tpoxx and those given a placebo. Researchers are now calling for the urgent development of alternative therapies, including combination antivirals and monoclonal antibodies, especially as severe outcomes remain high in under-resourced regions battling clade 1 mpox.

The world could stop central Africa’s deadly mpox outbreak if it wanted to

April 16, 2025

As global attention to mpox wanes, the virus continues to surge across Central Africa, particularly in the Democratic Republic of the Congo (DRC), where the more lethal clade I variant has caused over 16,000 cases and 500 deaths in 2024. Despite its severity, clade I has received little global investment in vaccines, diagnostics, or surveillance compared to clade IIb, which triggered global alarm in 2022. Scientists now warn of clade Ib, a new subvariant with increased transmissibility. Equitable vaccine access, rapid testing, and global coordination remain vital to stop the spread—before the outbreak jumps borders and becomes another preventable global crisis.

As Kenya awaits mpox vaccine roll-out, health workers drive rising public awareness of the virus

April 16, 2025

Kenya’s mpox outbreak, now confirmed in 13 counties, highlights the need for targeted public health interventions. Cases cluster along the Mombasa-Kampala transport corridor, disproportionately affecting sex workers and long-distance truck drivers. In Kiboko, a town on this route, local health workers identified mpox in a sex worker living with HIV, who later transmitted it to her children. Community-based surveillance, posters, and Red Cross support have helped stem transmission. On April 9, Kenya received 10,700 vaccine doses from Gavi. The rollout will prioritize vulnerable populations, but sustained community engagement and health education remain vital to curb this growing public health threat.

Mpox activity escalates in Uganda as vaccine shipments to Africa pass 1 million doses

April 11, 2025

Mpox continues to surge across Africa, with Uganda now accounting for half of all new cases, according to the Africa CDC. The continent is recording about 3,000 new cases weekly, driven largely by sexual transmission in densely populated urban areas. Uganda alone is grappling with concurrent outbreaks of mpox, Ebola, and Crimean-Congo hemorrhagic fever. While over 1 million vaccine doses have arrived across Africa, officials estimate 6.4 million are needed within six months to curb spread. Encouragingly, Uganda vaccinated 20,000 people in just one week. Testing challenges persist in conflict zones like eastern DRC, complicating surveillance and response efforts.

Vancouver Coastal Health urges mpox vaccinations amid recent increase in cases

April 9, 2025

Vancouver Coastal Health is urging men who have sex with men to ensure they are fully vaccinated against mpox, following a rise in cases. Nineteen infections have been reported in the region in 2025, most involving individuals who were unvaccinated or had only one vaccine dose. Officials emphasize that mpox, a virus related to smallpox, continues to circulate and spreads primarily through close personal contact. Less than half of eligible individuals have received both doses of the vaccine. With symptoms ranging from fever to painful rashes, health advocates stress the importance of awareness, community dialogue, and completing the two-dose series.

Switzerland confirms clade 1b mpox as Hong Kong issues warning

April 9, 2025

Switzerland has reported its first case of clade 1b mpox in a traveler returning from Africa, marking another addition to the list of countries detecting this more virulent strain. The patient is in isolation, and Swiss health officials confirm there is no risk of further transmission. Clade 1b is driving the current outbreak in central Africa, particularly in the Democratic Republic of the Congo. Meanwhile, the UK recently reported a clade 1b case with no travel history, prompting Hong Kong officials to issue public advisories. Clade 1b has now been detected in at least 15 countries across three continents.

How do mpox outbreaks start? Dead baby monkey provides important clue

April 8, 2025

A new preprint study has identified the fire-footed rope squirrel as a likely reservoir for mpox after an outbreak among mangabeys in Ivory Coast’s Taï National Park. Researchers traced the virus to a dead squirrel found months before the primate cases, suggesting cross-species transmission likely triggered the outbreak. The virus, previously believed to circulate primarily among rodents, may persist in rope squirrel populations. This breakthrough advances understanding of mpox’s zoonotic origins and raises questions about human-wildlife interactions in endemic areas. Scientists say this could help prevent future outbreaks by targeting surveillance and intervention where animal-to-human spillover risk is highest.

New Test Added to Recommended List of Molecular Diagnostic Tests for Mpox

April 7, 2025

Africa CDC has added the RADIONE Mpox Detection Kit to its list of recommended molecular diagnostic tests, marking a key advancement in expanding point-of-care (POC) diagnostics across the continent. Manufactured in South Korea by KH Medical, the test detects mpox DNA from clades I and II using automated PCR technology. It previously received WHO Emergency Use Listing in 2024 and passed independent evaluation in the DRC. With limited lab capacity still hindering timely diagnosis, this new addition supports the continent's six-month response plan focused on decentralizing testing and improving outbreak control amid ongoing mpox transmission in 22 African countries.

New 'surprising' case of mpox variant clade lb detected in England

April 7, 2025

The UK Health Security Agency (UKHSA) has confirmed a new clade 1b mpox case in northeast England, notably with no travel history or known connection to previous cases. Diagnosed in March, the patient’s contacts have been traced, and no additional cases have emerged. While UKHSA maintains that the public risk remains low, the unexplained transmission raises concerns about possible undetected community spread. Investigations are ongoing to determine the source of infection. The case underscores the need for continuous mpox surveillance and diagnostic preparedness, particularly as the clade 1b variant has proven more transmissible in other countries.

The Power of the Mpox Jab: Saving Lives in Kinshasa

April 7, 2025

In a groundbreaking move, the Democratic Republic of the Congo (DRC) became the first country to approve the MVA-BN (Jynneos) vaccine for children, launching a mass vaccination campaign in Pakadjuma targeting those aged 1 to 17. With support from Africa CDC, WHO, Gavi, and UNICEF, over 525,000 people were vaccinated—nearly 40% of them children. The campaign comes amid alarming statistics: children accounted for more than half of mpox cases and deaths in 2024. The DRC’s success, marked by high coverage and community trust, is a hopeful model for other nations now urged to approve pediatric use of MVA-BN.

Mpox case confirmed with no travel links

April 7, 2025

A Clade 1b mpox case has been confirmed in northeast England, with no known links to travel or existing cases, raising concerns about potential undetected community transmission. The UK Health Security Agency (UKHSA) is investigating the source of the infection, while maintaining that the overall public risk remains low. Though the disease was recently downgraded from its high-consequence infectious disease status, officials stress that mpox can still cause serious illness in some individuals. UKHSA urges the public to remain vigilant for symptoms such as rashes or fever and to seek medical advice if exposure or infection is suspected.

Mpox activity in Africa on pace to pass 2024 total

April 3, 2025

Mpox activity in Africa is escalating sharply, with nearly 50% of 2024’s total cases already reported in the first quarter of 2025, according to Africa CDC Director Dr. Jean Kaseya. Uganda, Burundi, and the Democratic Republic of the Congo (DRC) accounted for 95% of confirmed cases last week. In the DRC, only 18.4% test coverage further clouds the outbreak picture amid ongoing conflict and foreign aid cuts. Ghana also reported its first case in 11 weeks, prompting renewed surveillance efforts. Meanwhile, Africa CDC has launched a health financing strategy focused on boosting domestic investment, innovative levies, and regional vaccine production.

US FDA approves freeze-dried version of Bavarian Nordic's mpox, smallpox vaccine

March 31, 2025

The U.S. FDA has approved a freeze-dried version of Bavarian Nordic’s Jynneos vaccine for mpox and smallpox, a key development for long-term emergency preparedness. Unlike the liquid-frozen formulation approved in 2019, the freeze-dried version offers improved shelf life and easier storage and transportation, ideal for global stockpiling. Developed under a U.S. BARDA contract, deliveries will begin in late 2025. This milestone comes as WHO continues to classify mpox as a public health emergency, with over 25,000 confirmed cases globally in 2024, including four U.S. cases of the more transmissible clade Ib. Broader vaccine access and storage stability are now critical.

UK no longer deems clade 1 mpox 'high consequence'

March 19, 2025

The UK Health Security Agency (HSA) has downgraded clade 1a and 1b mpox, determining they no longer meet the criteria for a high-consequence infectious disease due to their low mortality rates and the availability of vaccines and treatments. However, the agency stresses that mpox remains a public health threat, particularly for travelers to affected regions. Meanwhile, a U.S. National Institutes of Health (NIH) trial confirmed that tecovirimat (Tpoxx), once considered a promising treatment for mpox, is ineffective for clade 2 infections. These findings underscore the need for continued research into effective treatments and global surveillance of mpox outbreaks.

Estimates: Jynneos mpox vaccine 84% and 35% effective in people without, with HIV

March 19, 2025

A recent study published in The Lancet Infectious Diseases found that a single dose of the Jynneos vaccine is 58% effective against mpox overall but significantly less effective (35%) in people with HIV compared to 84% in those without. Conducted across multiple countries, the study also highlighted reduced symptom severity and faster recovery in vaccinated individuals. Researchers stress the importance of completing a two-dose regimen, particularly for immunocompromised individuals. Experts call for expanded research in Central Africa, where clade 1 mpox is endemic, emphasizing the need for stronger vaccination strategies to protect high-risk populations and prevent global outbreaks.

USAID freeze impacting the transport of mpox diagnostics in Africa

March 18, 2025

The Democratic Republic of Congo (DRC) has reported that the U.S. funding freeze is severely impacting its efforts to contain the ongoing mpox outbreak. At the latest WHO emergency meeting, officials confirmed that the suspension of U.S. aid has disrupted laboratory diagnostics and sample transportation, leading to a decline in testing rates. The WHO has raised $65.6 million for response efforts, but $7.5 million remains inaccessible due to the freeze. As Africa CDC explores alternative funding sources, WHO Director-General Dr. Tedros Adhanom Ghebreyesus has urged the U.S. to reconsider its pause on international healthcare aid to prevent further public health setbacks.

Mpox case in Khyber not locally transmitted

March 17, 2025

Health officials in Khyber-Pakhtunkhwa, Pakistan, have confirmed five mpox cases, with one being the first confirmed local transmission in the province. A woman in Dogra, Khyber district, initially suspected of contracting the virus locally, was later found to have contracted it from her husband, who had recently returned from a Gulf country. Meanwhile, a 20-year-old man from Peshawar, with no travel history, represents the first locally transmitted case. Authorities have begun screening his contacts. With rising cases and potential community spread, health officials have isolated patients and initiated surveillance efforts to contain further transmission in the region.

Third meeting of the International Health Regulations (2005) Emergency Committee regarding the upsurge of mpox 2024

March 17, 2025

The World Health Organization (WHO) has reaffirmed that the 2024 mpox surge continues to meet the criteria of a Public Health Emergency of International Concern (PHEIC). The decision follows the third meeting of the International Health Regulations (IHR) Emergency Committee, which cited escalating cases, security challenges in the Democratic Republic of the Congo (DRC), and a freeze in U.S. funding as critical concerns. The outbreak, driven by the spread of MPXV clade Ib, remains uncontrolled, with travel-related cases detected globally. The WHO emphasized the need for sustained international collaboration, increased surveillance, and expanded vaccine access to mitigate the crisis.

The multi-partner Access and Allocation Mechanism allocates 238 000 doses of mpox vaccine to four countries

March 15, 2025

In response to the ongoing mpox crisis, the Access and Allocation Mechanism (AAM) has allocated an additional 238,000 vaccine doses to Angola, Guinea, Sierra Leone, and Uganda—four of the hardest-hit nations. This follows the initial November 2024 allocation of 899,000 doses to nine African countries. With mpox subclade Ib continuing to spread since its emergence in the Democratic Republic of the Congo, global coordination remains crucial. The AAM, supported by Africa CDC, WHO, Gavi, and other partners, is ensuring vaccine distribution to the most affected regions. This step is vital in containing outbreaks and reducing transmission across the continent.

Mpox vaccines are beginning to roll out in Uganda

March 14, 2025

Uganda’s mpox vaccination campaign is underway, with a targeted rollout prioritizing sex workers, who face heightened transmission risks and stigma. By March 4, Uganda had reported 3,833 cases and 31 deaths. The first 10,000 vaccine doses, received in January from the EU’s HERA, were administered in key hotspots like Kawempe and Makindye. More doses—100,000 in total—are expected this month to expand coverage, including healthcare workers. While awareness efforts continue, organizations like AWAC are urging authorities to ensure equitable access for vulnerable populations. Effective outreach and timely vaccine deployment remain crucial to containing Uganda’s mpox outbreak.

Tecovirimat is safe but ineffective as treatment for clade II mpox

March 12, 2025

A landmark clinical trial funded by the NIH has concluded that tecovirimat (TPOXX) monotherapy does not accelerate the resolution of clade II mpox lesions or improve pain management. The STOMP study, conducted across multiple countries, found no significant difference in recovery rates between those receiving tecovirimat and those given a placebo. These findings align with results from the PALM007 study in the Democratic Republic of Congo. The trial underscores the urgent need for alternative mpox treatments and improved understanding of disease progression. Future research should focus on combination therapies and factors influencing clinical outcomes to guide more effective treatment strategies.

Congo faces setback in mpox response after Rwanda-backed rebels advance in the east

March 11, 2025

The worsening security situation in eastern Congo has severely impacted mpox detection and treatment efforts. As Rwanda-backed M23 rebels advance, hospitals that once led the mpox response now struggle with shortages of medical supplies, disrupted vaccine distribution, and fleeing patients. The Miti Murhesa health zone, a major outbreak site, is among the worst affected, with only two of its four treatment centers operational. Authorities are negotiating a humanitarian corridor to restore medical access, but without immediate intervention, the outbreak risks further escalation. The crisis underscores the urgent need for international support to sustain Congo’s fragile healthcare system amid conflict.

Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate

March 10, 2025

Tonix Pharmaceuticals has secured a grant from the Medical CBRN Defense Consortium (MCDC) to advance TNX-801, a recombinant horsepox virus vaccine for mpox and smallpox. Designed for single-dose, long-term protection, TNX-801 aims to enhance patient compliance and ease of use. The funding will support market analysis and commercialization planning across private and government sectors. Amid the global spread of clade I mpox, which WHO reaffirmed as a Public Health Emergency of International Concern (PHEIC) in February 2025, this vaccine could play a critical role in outbreak prevention. Tonix’s innovation presents a promising step in strengthening global mpox defense strategies.

Mpox: Warning over ‘highly infectious’ new variant identified in Congo

March 6, 2025

A new mutated variant of Clade 1a Mpox, carrying the APOBEC3 mutation, has been identified in the Democratic Republic of Congo (DRC), raising concerns about increased transmissibility. Although less deadly than earlier Clade 1a strains, this variant appears highly infectious, with cases already detected in the UK. In response, a vaccination campaign was launched in Kinshasa to curb the spread, particularly in high-risk areas like Pakadjuma. However, USAID funding cuts and escalating conflict in eastern DRC have severely impacted containment efforts. Experts are calling for urgent international support for testing, vaccination, and public health education to prevent further global spread.

New mutant mpox strain discovered in the DRC

March 3, 2025

A new variant of Clade 1a mpox with the APOBEC3 mutation, which may enhance human-to-human transmission, has been identified in the Democratic Republic of Congo (DRC). This raises major public health concerns, as Clade 1a has historically caused more severe disease than other variants. Ongoing conflict in the DRC has further disrupted response efforts, forcing over 500 patients to flee clinics. Testing coverage has plummeted to 35%, and Uganda’s rising cases have overwhelmed hospitals, prompting at-home treatment initiatives. Amid these challenges, the first large-scale vaccination campaign in the DRC has begun, delivering 24,800 doses in four days.

Africa CDC’s Emergency Consultative Group Recommends Continuation of Mpox as a Public Health Emergency of Continental Security

February 28, 2025

The Africa CDC’s Emergency Consultative Group (ECG) has unanimously recommended maintaining Mpox as a Public Health Emergency of Continental Security (PHECS) due to rising cases, wider spread, and a highly transmissible new variant. Since August 2024, cases have tripled, spreading to nine additional African countries, exacerbated by testing gaps, vaccine shortages, and U.S. aid suspensions. The Clade Ia (APOBEC3) variant presents a growing threat, while fragile health systems battle simultaneous outbreaks of Ebola, Marburg, measles, and cholera. Africa CDC is intensifying efforts in vaccine distribution, surveillance, and laboratory decentralization to contain Mpox’s spread and mitigate the worsening crisis.

DR Congo conflict: 500 mpox patients flee clinics after rebel looting

February 28, 2025

The ongoing conflict in eastern Democratic Republic of Congo (DRC) has severely disrupted mpox containment efforts, with more than 500 patients fleeing clinics over the past month. Africa CDC officials warn that the missing patients pose a serious risk of spreading the highly contagious disease, which claimed an estimated 900 lives in DRC last year. Fighting in Goma and Bukavu has led to looted health facilities, destroyed records, and shortages of critical medical supplies. With a newly detected mpox variant of heightened transmissibility, experts urge an immediate ceasefire and humanitarian corridors to restore outbreak control and protect vulnerable communities.

Mpox still a health emergency, says WHO

February 27, 2025

The World Health Organization (WHO) reaffirmed on Thursday that the ongoing mpox outbreak remains a public health emergency, citing the rising number of cases and expanding geographic spread. Violence in eastern Democratic Republic of Congo (DRC), the epicenter of the outbreak, has severely hindered containment efforts. The highly transmissible Clade Ib variant continues to spread, affecting Uganda and Burundi, with travel-related cases reported in Thailand and Britain. With over 21,000 confirmed cases and 70 deaths in 2024 alone, experts warn that inadequate surveillance could worsen the crisis. WHO urges global vigilance to prevent further escalation of this health emergency.

Third meeting of the International Health Regulations (2005) Emergency Committee regarding the upsurge of mpox 2024 – Temporary recommendations

February 27, 2025

The World Health Organization (WHO) has reaffirmed that the mpox outbreak remains a global health emergency following the third International Health Regulations (IHR) Emergency Committee meeting. WHO has issued a revised set of temporary recommendations focusing on emergency coordination, enhanced surveillance, clinical care, cross-border collaboration, vaccination, and community engagement. These measures aim to curb transmission, particularly in hotspots affected by the Clade Ib variant. WHO urges governments to commit resources, strengthen health systems, and combat stigma while integrating mpox response into broader disease control efforts. Quarterly reporting on progress is mandated to ensure accountability and effective global coordination.

Why the good news about the mpox outbreak of 2025 isn't really good after all

February 25, 2025

The mpox outbreak in the Democratic Republic of Congo (DRC) is spiraling out of control amid escalating violence and a freeze on U.S. foreign aid, warns Africa CDC Director Dr. Jean Kaseya. Over 400 mpox patients have fled isolation centers in Goma as fighting disrupts treatment and surveillance efforts. The abrupt halt in U.S. funding, coupled with the U.S. withdrawal from WHO, has stalled vaccine deliveries and critical lab testing. With mpox cases rising and healthcare systems collapsing, experts fear global ramifications if the outbreak isn't contained. Dr. Kaseya cautions, "We are playing with fire."

New mpox variant can spread rapidly across borders

February 20, 2025

The rapid evolution of the mpox virus in the Democratic Republic of the Congo (DRC) has sparked global concern as the newly identified clade 1b variant shows increased transmissibility and has spread beyond borders to countries like Sweden and Thailand. Research published in Nature Medicine highlights that clade 1b, first detected in September 2023, now includes three subvariants and poses heightened risks, including increased miscarriages among pregnant women. The virus is spreading primarily through heterosexual contact in densely populated areas, affecting men, women, healthcare workers, and children. Experts urge immediate cross-border cooperation, expanded vaccination, and public education to prevent a wider global outbreak.

Trump’s dismantling of USAID raises risk of mpox global emergency, experts warn

February 20, 2025

The dismantling of USAID by the Trump administration and the suspension of U.S. global health aid is escalating the risk of mpox becoming a wider global emergency. With USAID’s departure from the Democratic Republic of Congo (DRC) and the freezing of $55 million in emergency funds, critical efforts in vaccination, testing, and surveillance have been halted. Health experts warn that this abrupt withdrawal leaves vulnerable regions without resources, undermines containment efforts, and heightens the risk of global spread. The loss of U.S. leadership in disease control, combined with severed ties to WHO, jeopardizes global health security.

Mpox risks rise in DR Congo conflict area, large cities in other nations

February 20, 2025

The ongoing conflict in South Kivu, Democratic Republic of the Congo (DRC), has forced 400 mpox patients to flee treatment centers, escalating the risk of regional spread, warns Africa CDC. The crisis has destroyed four healthcare facilities and displaced over 153,000 people, halting mpox reporting in the region. With outbreaks in 22 African countries, cases are surging in six, including Uganda and Zambia. Although more than 200,000 vaccine doses have been administered, U.S. aid disruptions hinder sample transport and response efforts. The newly launched African Epidemic Fund offers hope for streamlined resources and local vaccine manufacturing.

US funding pause impedes mpox response in DR Congo

February 14, 2025

The Democratic Republic of the Congo (DRC) is facing a worsening mpox crisis as armed conflict disrupts sample transport, lab testing, and healthcare services, according to Africa CDC. Ongoing violence in and around Goma has caused displaced populations, including mpox patients, to flee, compounding the outbreak. A US funding freeze has further crippled response efforts, forcing African leaders to seek alternative funding from China, Japan, and South Korea. Meanwhile, Uganda shows promising vaccine uptake, with 9,000 of 10,000 doses administered. Africa CDC urges caution as data remains incomplete due to testing disruptions, calling for urgent global cooperation to prevent wider spread.

Mpox Patients Fleeing Goma Hospitals In DRC Violence

February 14, 2025

The escalating conflict in eastern Democratic Republic of Congo (DRC) has forced 128 mpox patients to flee isolation units in Goma, raising urgent concerns about virus transmission amid violent unrest. The World Health Organization (WHO) confirmed 1,348 mpox cases in the DRC this year, with the deadly clade 1b variant at the epicenter in Kivu. The conflict, driven by M23 rebels backed by Rwandan forces, has devastated health infrastructure, leaving displaced civilians without aid. With thousands in overcrowded shelters and humanitarian access severely restricted, the WHO and UNHCR are calling for immediate action to prevent further health crises.

McGill awards $500,000 to accelerate Mpox research and vaccine development

February 13, 2025

McGill University’s DNA to RNA Initiative (D2R) and the McGill Interdisciplinary Initiative in Infection and Immunity (MI4) have awarded $500,000 to fund five groundbreaking research projects aimed at improving mpox understanding and vaccine development. The research focuses on immune responses, vaccine targets, mRNA vaccine advancements, and virus-host interactions. With mpox continuing to spread globally, these studies are crucial in enhancing pandemic preparedness. Led by McGill scientists, the projects seek to develop novel RNA-based vaccines, assess immunity from prior smallpox vaccinations, and create innovative therapeutic strategies to combat evolving mpox variants, ensuring stronger public health interventions.

Mpox outbreak in Africa at critical moment as U.S. halts aid, rebel violence erupts

February 12, 2025

The ongoing mpox outbreak in Africa faces a dire turning point as U.S. foreign aid is halted and rebel violence in the Democratic Republic of Congo (DRC) disrupts containment efforts. Previously, global partnerships, including the U.S., Japan, and France, provided crucial support, with a million vaccine doses pledged. However, recent rebel attacks have forced over 100 patients to flee treatment centers, heightening transmission risks. The loss of USAID funding has further stalled interventions, leaving vaccines stranded in warehouses. Experts warn that without immediate action, the crisis could spread beyond Africa, jeopardizing global health security.

Mpox: Scientists offer better understanding of tecovirimat resistance

February 12, 2025

Scientists at the Institut Pasteur have made a breakthrough in understanding resistance to tecovirimat, the primary antiviral used to treat mpox. Their study, published in Nature Microbiology, reveals how the drug interacts with the F13 enzyme, which some viral strains mutate to develop resistance. This research is crucial as mpox cases surge in the Democratic Republic of Congo and beyond, with WHO declaring another global public health emergency in August 2024. By uncovering tecovirimat’s mechanism of action, researchers are paving the way for the development of new, more effective antiviral treatments that can combat resistant mpox strains worldwide.

CDC says person diagnosed with new mpox variant in New York is in isolation

February 12, 2025

The Centers for Disease Control and Prevention (CDC) has confirmed that a patient diagnosed with clade 1b mpox in New York is in isolation and recovering without specific treatments. This marks the fourth confirmed U.S. case of this highly transmissible strain, following previous detections in California, Georgia, and New Hampshire. The patient had recently traveled from East Africa, a known mpox hot spot. The World Health Organization declared mpox a global public health emergency in August 2024 due to its rapid spread from the Democratic Republic of the Congo to neighboring countries, heightening concerns about further international transmission.

Clade 1b mpox outbreak in DR Congo linked to sex workers; New York reports first case

February 12, 2025

New research published in Nature Medicine sheds light on the clade 1b mpox outbreak in the Democratic Republic of the Congo (DRC), revealing that 83% of cases were linked to sex work and that pregnant women frequently miscarried after contracting the virus. The study, based on 670 hospitalized patients in South Kivu, also reported three healthcare worker infections and seven deaths, four of which were in young adults. Meanwhile, New York has confirmed its first case of clade 1b mpox in a resident who recently traveled to East Africa, marking the fourth such case in the United States, all travel-related.

From Mpox to Influenza – USAID Collapse and CDC Blackout Upend WHO Response to Deadly Outbreaks

February 12, 2025

The World Health Organization (WHO) is grappling with severe challenges in responding to global health crises, including the deadly mpox outbreak in the Democratic Republic of Congo (DRC), following the collapse of U.S. funding and cooperation. The sudden halt of USAID support has crippled humanitarian efforts in Uganda, DRC, and beyond, affecting disease surveillance, vaccine rollouts, and emergency responses. Meanwhile, the U.S. Centers for Disease Control and Prevention (CDC) has ceased sharing influenza data, hindering global preparedness for seasonal flu. WHO officials stress the urgent need for continued international collaboration, warning that the loss of U.S. partnerships could significantly weaken global health security.

New York health department confirms first case of new mpox strain

February 11, 2025

New York has confirmed its first case of the newly emerging mpox strain, clade Ib, adding to growing global concerns over its spread. This case marks the fourth confirmed U.S. infection, following reports in California, Georgia, and New Hampshire. The U.S. Centers for Disease Control and Prevention (CDC) has stated that these cases are unrelated. The World Health Organization (WHO) declared mpox a global public health emergency in August 2024 after outbreaks surged in the Democratic Republic of Congo and neighboring countries. While New York health officials have not disclosed further details, the case underscores the need for continued vigilance and preventive measures.

Government of Canada and Gavi deliver 200,000 doses of donated mpox vaccine to DRC

February 11, 2025

The Democratic Republic of the Congo (DRC) has received a crucial shipment of 200,000 mpox vaccine doses, donated by Canada and coordinated by Gavi, the Vaccine Alliance. This delivery, part of the Access and Allocation Mechanism, aims to bolster vaccination efforts in the epicenter of the outbreak. Canada’s Minister of International Development, Ahmed Hussen, reaffirmed Canada’s commitment with an additional $1 million in funding to support WHO’s regional mpox response. With over 19,800 confirmed cases across 21 African nations, targeted vaccination efforts are critical to controlling the epidemic and protecting vulnerable communities in the DRC and beyond.

Third mpox diagnosis in U.S. found in N.H. by health departments

February 8, 2025

New Hampshire has confirmed its first case of clade I mpox in a Merrimack County resident who recently traveled to Eastern Africa, where outbreaks of this more severe strain are ongoing. The individual is recovering in self-isolation, and health officials assure there is no public risk or evidence of local transmission. The Department of Health and Human Services (DHHS) is conducting contact tracing and offering preventive vaccination to those exposed. With mpox continuing to spread in Africa, health officials stress the importance of awareness, vaccination, and early detection, particularly for travelers to affected regions.

Conjunctivitis, impaired vision top mpox complications of the eyes

February 7, 2025

A new meta-analysis published in the Journal of Infectious Diseases highlights conjunctivitis as the most common mpox-related eye complication, followed by impaired vision, keratitis, and eye lesions. Researchers stress the need for early recognition, routine eye exams, and timely treatment, particularly in endemic regions like Africa and among immunocompromised patients. The study underscores the risk of keratitis, which, if untreated, can lead to corneal ulceration and vision loss. Experts call for preventive strategies such as vaccination and antiviral treatments to mitigate disease severity and complications, emphasizing the necessity of further research to refine clinical guidelines and interventions.

South Sudan declares mpox outbreak

February 7, 2025

South Sudan has officially declared an Mpox outbreak in Juba, Central Equatoria State, following the confirmation of a case on February 6, 2025. The Ministry of Health, in collaboration with WHO, has launched a coordinated response, including contact tracing, laboratory testing, and enhanced surveillance at major entry points. WHO has deployed experts and provided technical and logistical support, ensuring rapid containment efforts. Training for healthcare workers is underway, with 40 clinicians already equipped for case management. Authorities urge the public to practice preventive measures as South Sudan becomes the 22nd African country affected by the ongoing Mpox outbreak.

Armed conflict disrupts mpox response in DR Congo

February 6, 2025

Africa CDC officials report escalating challenges in the Democratic Republic of the Congo’s (DRC) North Kivu province, where intense conflict is hampering mpox response efforts. Patients fleeing treatment centers and disruptions in lab testing have led to underreporting. Meanwhile, Uganda and Zambia are experiencing rising cases, with Uganda’s outbreak driven by sexual transmission networks, complicating contact tracing. Despite this, mpox vaccination efforts have resumed in Goma and Kampala, offering hope. The Biden Administration has disbursed $340 million of its pledged $500 million, yet concerns remain as new U.S. foreign aid policies under President Trump threaten future support.

First case of newer mpox variant detected in Ireland

February 6, 2025

Ireland has detected its first case of Clade 1 Mpox in a resident who recently returned from the Democratic Republic of Congo. The Health Service Executive (HSE) reassures the public that the risk remains low, with the patient receiving specialist care in Dublin. While Clade 1 is more transmissible and severe than Clade 2, those vaccinated or previously infected are considered protected. Ireland has recorded only eight Clade 2 cases in 2025. Global health officials remain concerned about the ongoing outbreaks in Africa, prompting mass vaccine shipments. Ireland continues to monitor the situation closely, ensuring rapid response capabilities.

First case of Clade I Mpox detected in Ireland as HSE says risk to public 'remains low'

February 6, 2025

Ireland has confirmed its first case of Clade I Mpox in a resident who recently traveled to the Democratic Republic of Congo. The Health Service Executive (HSE) assures the public that the risk remains low, as close contacts are being monitored. While Ireland previously recorded cases of Clade II Mpox during the 2022 outbreak, this is the first detection of the more severe Clade I strain. The HSE has been preparing for such cases since August 2024, working closely with international health bodies. Individuals returning from affected regions are advised to monitor symptoms for three weeks and seek medical attention if needed.

Case study: Mpox in nursing home worker resulted in no spread

February 5, 2025

A new study in the American Journal of Infection Control highlights the effectiveness of standard infection control measures in preventing mpox transmission in healthcare settings. In 2023, a Kentucky nursing home worker with mpox exposed up to 56 residents while providing direct care, yet no secondary infections occurred. The facility implemented post-exposure prophylaxis (PEP) with Jynneos vaccine for nearly half of the residents, but researchers suggest that adherence to standard precautions—such as glove use—was the primary factor in preventing transmission. This case underscores the importance of routine infection control measures in reducing the risk of mpox spread in healthcare environments.

Sierra Leone’s mpox outbreak puts Ebola, COVID-19 lessons to the test

February 5, 2025

Sierra Leone’s health workers are leveraging past experiences from the Ebola and COVID-19 epidemics to contain a growing mpox outbreak, with 20 cases confirmed since the public health emergency declaration on January 13. Authorities have established treatment centers, activated testing facilities, and strengthened contact tracing across seven affected districts. Surveillance systems and district emergency operations centers have been reactivated, ensuring rapid response to emerging cases. International partners, including WHO and Save the Children, are supporting vaccine procurement, training health workers, and educating the public. These coordinated efforts aim to contain mpox, protect vulnerable populations, and prevent further transmission.

NHS opens 12 more mpox vaccination centres

February 4, 2025

The expansion of mpox vaccination sites across England marks a significant step in ensuring wider access to protection against the virus. Previously limited to London, Brighton, and Manchester, the NHS has now opened 12 additional sites, allowing more eligible individuals—primarily men who have sex with men with multiple partners—to receive the vaccine. This move follows the detection of Clade 1b mpox in England in October 2024, a strain distinct from the one circulating at low levels since 2022. With mpox spreading through close skin contact and bodily fluids, the NHS urges those at higher risk to get vaccinated promptly.

UK reports 9th clade 1b mpox case

February 4, 2025

The UK Health Security Agency (HSA) has confirmed the ninth case of Clade 1b mpox in the country since October 2024, involving a traveler returning from Uganda, a current outbreak hotspot. This marks the fourth such case reported since January 20. Moving forward, the HSA will transition from case-by-case reporting to weekly updates every Thursday. While officials stress that the risk to the general UK population remains low, they continue to monitor close contacts and provide guidance to prevent further spread. Clade 1b, first identified in the Democratic Republic of the Congo, continues to drive large outbreaks in Africa.

As mpox vaccine centres open across England, here’s who is eligible for a jab

February 3, 2025

The UK’s mpox vaccination program has expanded nationwide, with 12 new sites providing broader access to high-risk individuals. Previously limited to London, Brighton, and Manchester, the initiative now reaches all regions of England, strengthening defenses against the virus. The UK Health Security Agency (UKHSA) maintains that the risk to the general population remains low, but proactive measures, including securing additional vaccine doses, aim to curb potential outbreaks. Eligible individuals, including men who have sex with men and those in high-risk settings, are encouraged to book appointments through the NHS. This expansion underscores the UK’s commitment to public health preparedness.

Eastern DR Congo crisis increasing risk of mpox transmission, WHO chief warns

February 3, 2025

The escalating conflict in the Democratic Republic of the Congo (DRC) has severely disrupted mpox treatment efforts, forcing patients to flee healthcare facilities and heightening transmission risks. As M23 rebels advance in North and South Kivu, critical infrastructure is collapsing, with hospitals overwhelmed by casualties and disease outbreaks, including cholera and malaria. Water, electricity, and medical supplies are running low, while displaced populations face dire conditions. The World Health Organization (WHO) and humanitarian agencies are struggling to maintain services amid the violence. Urgent international intervention is needed to restore stability, protect public health, and prevent further humanitarian catastrophe.

Has Britain’s mpox risk been exaggerated?

February 2, 2025

The UK Health Security Agency’s (UKHSA) handling of recent mpox cases has raised concerns about excessive response measures. Two businessmen returning from Uganda with mild symptoms were subjected to stringent protocols, including forced isolation, convoy transport, and warnings to dispose of household items. Despite mpox’s low fatality rate (0.2%) and unclear differences in severity between Clade 1 and Clade 2 strains, UKHSA maintains that its classification as a high-consequence infectious disease justifies these actions. As debate continues over proportionality and legal authority, a reassessment of the UK’s mpox policies is needed to balance public health protection with individual rights.

New case of mpox variant clade lb detected in England

January 31, 2025

The United Kingdom has confirmed its eighth Clade 1b mpox case, linked to recent travel from Uganda, where community transmission remains active. The UK Health Security Agency (UKHSA) maintains that the overall risk to the public remains low but acknowledges that imported cases are expected given the outbreak in parts of Africa. With the World Health Organization classifying Clade 1b as a global health emergency, the continued detection of cases underscores the need for vigilant border health measures, proactive public health response, and enhanced global cooperation to prevent further international spread.

UK reports another imported clade 1b mpox case

January 28, 2025

The United Kingdom has reported its seventh Clade 1b mpox case, linked to travel from Uganda, reinforcing concerns about the virus’s continued spread. While the UK Health Security Agency assures that the risk remains low, close contacts are being monitored. Meanwhile, the World Health Organization (WHO) highlights ongoing transmission in the Democratic Republic of the Congo (DRC), Burundi, and Uganda, where escalating violence hampers response efforts. Travel-related cases underscore the need for heightened surveillance and global coordination to contain the outbreak. With sustained circulation in Africa, urgent action is required to mitigate international transmission risks.

Mpox in the DRC: residents of the slum at the centre of Kinshasa’s epidemic have little chance of avoiding this major health crisis

January 24, 2025

Kinshasa, the Democratic Republic of Congo's sprawling megacity, faces a dual-strain mpox outbreak, complicating containment efforts. Clade Ia, spread through zoonotic and household transmission, and Clade Ib, linked to sexual contact, coexist in hotspots like Pakadjuma. Addressing the crisis requires tailored interventions: blanket vaccinations for high-transmission zones, community engagement to reduce stigma, and logistical support for home care. Médecins Sans Frontières triage centers and robust lab networks are pivotal, but overwhelmed resources and cultural challenges hinder progress. Without immediate action, including amplified awareness campaigns and systemic support, the epidemic risks spiraling further in this densely populated urban landscape.

Patient zero: How one doctor helped uncover the origin of the DRC’s mpox outbreak

January 23, 2025

Dr. Leandre Murhala Masirika’s investigation into South Kivu’s wildlife for mpox took an unexpected turn when the first human case of a new, more virulent clade, 1b, emerged in Kamituga, Democratic Republic of Congo. The outbreak rapidly escalated, with bars and sex workers as epicenters, overwhelming healthcare facilities. Despite limited resources, Dr. Masirika spearheaded epidemiological research and containment efforts, even using personal funds to support patients. By December 2024, over 55,000 vaccines were administered, but children remain disproportionately affected. As researchers probe the origins and transmission of clade 1b, Dr. Masirika continues his vital work, emphasizing the global stakes of this crisis.

Central African Republic launches mpox vaccination; cases rise in Uganda

January 23, 2025

Mpox cases in Africa remain persistent, with 21 countries reporting cases since 2024, including 10 actively battling outbreaks, according to Africa CDC. The Central African Republic launched its mpox vaccine campaign on January 18, administering 2,300 doses from a 12,300-dose allocation. Uganda, facing rising cases and deaths, particularly among vulnerable groups, joins urban centers like Kampala, Kinshasa (DRC), and Bujumbura (Burundi) as critical intervention zones. Sierra Leone, now with 12 confirmed cases, revealed clade 2b as its dominant strain. The DRC and its neighbors are also contending with the emergent clade 1b strain. Focused, clade-specific interventions are urgently needed.

Mpox: Uganda Receives 10,000 Doses of Vaccines to Combat Outbreak

January 23, 2025

The European Commission, through its Health Emergency Preparedness and Response Authority (HERA), has delivered 10,000 MVABN® vaccine doses to Uganda to combat its escalating Mpox outbreak. Uganda has reported over 1,000 confirmed cases since July 2024, with fatalities rising to 10, placing immense pressure on the healthcare system. This shipment, part of HERA's donation of over 215,000 doses to Africa CDC, underscores the critical role of international solidarity in addressing public health emergencies. With 60% of infections concentrated in the Kampala Metropolitan Area, this intervention aims to curb the spread and protect vulnerable populations across the region.

Ugandan advocacy groups step up fight against mpox

January 22, 2025

As mpox cases surge in Uganda, LGBTQ rights organizations are raising alarms over its disproportionate impact on queer communities, especially in semi-urban areas. The Uganda Key Populations Consortium (UKPC), working with the Health Ministry and WHO, warns that stigma and discrimination are deterring individuals from seeking care, exacerbating the crisis. Uganda has reported 2,127 cases and 12 deaths, with Kampala as the epicenter. UKPC and its partners are integrating mpox response with HIV care, launching tailored health surveys, and combating misinformation. Despite a challenging homophobic climate, proactive efforts by LGBTQ organizations are empowering marginalized communities with education and support.

Texas A&M And University Of Minnesota Researchers Receive $3.8M To Develop New Mpox Treatment

January 22, 2025

Researchers from Texas A&M and the University of Minnesota have received a $3.8 million NIH grant to develop new antiviral treatments for mpox, which continues to devastate parts of Central and Eastern Africa despite a global decline in cases. The project will evaluate three promising compounds, optimizing their efficacy and safety to address gaps in current smallpox-based treatments, which are largely ineffective against mpox. Mpox, particularly Clade I, has shown increased transmissibility and higher fatality rates, emphasizing the urgent need for innovative solutions. This research not only targets immediate threats but also strengthens preparedness against future orthopoxvirus outbreaks.

HERA delivers mpox vaccines to support Uganda’s outbreak response

January 21, 2025

The European Commission, through HERA, has delivered 10,000 doses of the MVA-BN® vaccine to Uganda as part of its coordinated response to the mpox outbreak. This contribution is part of a larger initiative involving over 215,000 doses donated to Africa CDC to combat the crisis across Africa. The delivery aligns with Team Europe’s commitment to global health security, exemplified by previous shipments to the DRC and Rwanda. Laurent Muschel, HERA’s head, and Dr. Jean Kaseya of Africa CDC emphasized the power of international collaboration in protecting vulnerable populations and strengthening preparedness for current and future health threats.

New case of mpox variant clade Ib detected in England

January 20, 2025

The UK Health Security Agency (UKHSA) has confirmed a sixth case of the mpox variant Clade Ib in England since October 2024. The latest case, identified in East Sussex, involves a patient who recently returned from Uganda, where community transmission of the variant is ongoing. Notably, this case has no links to the previous five. The Clade Ib variant, declared a global health emergency by the World Health Organization in August 2024, spreads more easily between people. While the UKHSA maintains that the risk to the general population remains low, the agency continues efforts to monitor and control potential transmission.

New case of more spreadable mpox detected

January 20, 2025

The UK Health Security Agency (UKHSA) has confirmed a new case of Clade Ib mpox in East Sussex, bringing the total number of cases in England to six since October 2024. The individual, recently returned from Uganda where the virus is spreading, is receiving specialist care at Guy’s and St Thomas’ NHS Foundation Trust. Clade Ib mpox, first detected in Central Africa, spreads more easily through human contact and presents with symptoms such as fever, pus-filled lesions, and fatigue. While UKHSA Deputy Director Dr. Meera Chand assures the public that the risk remains low, contact tracing efforts are underway to contain potential spread.

First mpox case detected in Azerbaijan, Interfax reports

January 18, 2025

Azerbaijan has reported its first case of mpox in 2025, involving a 22-year-old man recently returned from a tourist trip abroad. Health authorities, including the Ministry of Health and TABIB, confirmed the patient is isolated and receiving hospital care in Baku. Symptoms include fever, rash, muscle pain, and swollen lymph nodes. Family members who had contact with the patient are under home observation, showing no symptoms. Mpox, typically mild but potentially lethal, spreads through close contact. This case underscores the ongoing global mpox challenge following its designation as a public health emergency by the WHO in August 2024.

Mpox: WHO Health Emergency Appeal 2025

January 16, 2025

The World Health Organization (WHO) declared Mpox a Public Health Emergency of International Concern in 2024, mobilizing a robust global response. The Mpox Global Strategic Preparedness and Response Plan emphasizes vaccination, enhanced diagnostics, and community engagement to curb the virus. In the Democratic Republic of Congo, over 50,000 individuals in high-risk areas have been vaccinated, with WHO experts supporting local healthcare systems. Investments in laboratory infrastructure, infection prevention training, and culturally sensitive education are combating stigma and misinformation. Global partnerships, including Gavi and the European Commission, ensure equitable vaccine distribution, highlighting WHO’s commitment to safeguarding vulnerable populations worldwide.

Enrollment Starts in Africa CDC-LED Mpox Therapeutic Study (MOSA)

January 15, 2025

Africa CDC, in collaboration with PANTHER and INRB, has launched the MOSA trial in the Democratic Republic of Congo, marking a significant milestone in combating Mpox. With the support of EU funding and Africa CDC leadership, the trial evaluates brincidofovir's safety and efficacy, addressing the urgent need for therapeutics as Mpox cases rise across Africa. Enrolling children and adults in high-risk areas, this adaptive study ensures rapid, evidence-based decision-making. As Africa takes ownership in advancing Mpox research, the MOSA trial reflects a groundbreaking step toward solutions, reinforcing the continent’s leadership in addressing public health challenges through innovative research.

Transmission of monkeypox virus clade I: overall risk remains low in the EU/EEA

January 14, 2025

The European Centre for Disease Prevention and Control (ECDC) reports 11 cases of MPXV clade I in the EU/EEA since August 2024, predominantly travel-associated or linked to household contacts. With mild symptoms observed in all cases, the risk of severe outcomes remains low. However, increased transmission in the Democratic Republic of Congo and neighboring areas underscores the need for vigilance. Travelers to affected regions should practice strict hygiene, monitor symptoms for 21 days, and seek healthcare if needed. Awareness campaigns targeting travelers and healthcare providers are critical to early diagnosis, containment, and effective public health responses.

Sierra Leone declares emergency after confirming 2nd mpox case in 4 days

January 13, 2025

Sierra Leone declared a state of emergency following two mpox cases within four days, signaling rising concerns about viral spread. Both patients, treated in Freetown, had no recent contact with infected animals or individuals, with only one having traveled recently. Mpox, initially confined to Central and West Africa, has seen unprecedented global spread since 2022, with transmission confirmed via sexual contact. Sierra Leone, already bearing scars from the 2014 Ebola crisis, must act swiftly to strengthen its healthcare system, strained by past epidemics. This emergency underscores the ongoing need for vigilance, robust health infrastructure, and international collaboration to combat outbreaks.

Malaysia records first Mpox case of 2025, total hits 12 since 2023

January 11, 2025

Malaysia’s Ministry of Health (MOH) has reported its first mpox case of 2025, involving a 24-year-old man who recently traveled abroad. This marks the country’s 12th case since July 2023, with previous cases including nine in 2023 and two in 2024. All reported cases are of the clade II variant. The patient is in stable condition and receiving hospital care. MOH reassures the public that it is monitoring the situation locally and globally and urges citizens to stay informed through official updates. This highlights the ongoing need for vigilance and public awareness regarding infectious diseases like mpox.

Sierra Leone reports first case of mpox

January 11, 2025

Sierra Leone has reported its first confirmed mpox case since the World Health Organization’s 2024 global health emergency declaration. The patient, a 27-year-old man from the Western Zone near Freetown, is in isolated care while health teams trace contacts and investigate potential exposure. Authorities have launched a public awareness campaign, intensified surveillance in affected areas, and provided protective equipment and training for healthcare workers. This marks a significant challenge for a country still rebuilding its health systems after the devastating Ebola epidemic of 2014-2016. Swift containment efforts highlight Sierra Leone's commitment to preventing further spread and protecting public health.

China discovers cluster of new mpox strain

January 9, 2025

China’s health authorities have detected a new mutated mpox strain, clade Ib, linked to a cluster outbreak originating from a foreigner with travel history to the Democratic Republic of the Congo (DRC). Four additional cases were identified among close contacts, with symptoms including rashes and blisters. This strain, which spreads more easily through close contact, has prompted global concern after the World Health Organization declared mpox a public health emergency last year. China’s National Health Commission has classified mpox as a Category B infectious disease, empowering officials to implement emergency measures to curb outbreaks and prevent further transmission.

Leveraging collaboration to combat mpox among Uganda’s most vulnerable communities

January 6, 2025

Uganda’s innovative response to the mpox outbreak emphasizes inclusivity, targeting Key Populations (KPs) such as sex workers, who face heightened risks due to stigma and limited healthcare access. The World Health Organization (WHO) partnered with MARPI Clinic Mulago to empower KPs through education and engagement. Initiatives included training staff, civil society managers, and community peers to identify symptoms, report cases, and facilitate care. This peer-based approach bridged gaps in trust and access, saving lives and fostering a sustainable public health response. Uganda’s collaboration showcases how tailored strategies can effectively protect marginalized groups during public health emergencies.

France identifies first case of new mpox variant, AFP reports

January 6, 2025

France has confirmed its first case of the mpox clade 1b variant, a new form of the virus linked to the global health emergency declared by the World Health Organization in August. The patient, a woman in Brittany, had no travel history to Central Africa, where the variant originated, but was in contact with individuals returning from the region. Health authorities are investigating the infection source and tracing potential contacts. This follows similar cases reported in neighboring Germany and Britain, highlighting the variant’s growing presence in Europe and the need for vigilance to prevent further spread.

Nepal reports two mpox cases among migrant workers

January 3, 2025

Nepal has confirmed two new mpox cases among migrant workers, raising its total to three since the first recorded case in 2023. Health authorities, including Dr. Sher Bahadur Pun of Sukraraj Tropical and Infectious Disease Hospital, highlight the vulnerability of Nepali workers in Gulf countries due to poor living conditions and limited healthcare access. The global mpox outbreak, declared a public health emergency by the World Health Organization, has affected over 100,000 people across 122 countries. Nepal’s health officials call for strengthened surveillance and awareness to combat the spread of this disease, which is transmitted through close contact.

How China is Trying to Contain Mpox Virus Spread

January 2, 2025

China’s comprehensive response to the ongoing mpox outbreak demonstrates a proactive public health approach. Since June 2023, the virus has predominantly affected men who have sex with men, with cases concentrated in Guangdong Province. Key measures include stringent surveillance at ports, contact tracing, and quarantine for confirmed cases. Public education campaigns and emergency drills ensure rapid response readiness. As a Class B infectious disease, mpox management now benefits from multi-departmental coordination. However, concerns about governmental transparency persist, fueling public anxiety reminiscent of COVID-19 lockdowns. Despite challenges, China’s strategy emphasizes early detection, community awareness, and international collaboration to curb mpox transmission.

TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses

January 2, 2025

The approval of TEPOXX (tecovirimat) in Japan for treating smallpox, mpox, cowpox, and smallpox vaccination complications marks a pivotal advancement in public health preparedness. SIGA Technologies, in collaboration with Japan Biotechno Pharma, achieved this milestone through rigorous clinical trials involving over 800 healthy volunteers and animal studies demonstrating efficacy.

With a long shelf life and targeted antiviral action against orthopoxviruses, TEPOXX strengthens Japan's national stockpile and readiness for outbreaks. This accomplishment reflects the significance of stockpiling effective antiviral therapies to combat infectious diseases and underscores global efforts to safeguard public health against orthopoxvirus-related threats.

Survey finds high hesitancy toward mpox vaccination in Africa

January 2, 2025

A recent survey published in eClinicalMedicine highlights significant hesitancy toward mpox vaccination in Africa. Conducted across six countries, the study revealed that 32.7% of adults were reluctant to vaccinate themselves, while 38.9% hesitated to vaccinate their children. Factors such as low education, unemployment, and lack of prior vaccination experience correlated with increased hesitancy. However, the 7Cs model demonstrated that high vaccination readiness could reduce hesitancy, even in those without prior vaccination history. With only 5% mpox vaccine uptake in 2023, the findings emphasize the urgent need for enhanced vaccination education and readiness to combat hesitancy and bolster Africa’s immunization efforts.